ZNTL Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. (ZNTL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $10.0M.
Where they traded
Last open-market purchase: August 14, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Buy | 4,335,000 | $3.50 | $15.2M | 17,844,973 | |||
| Vultaggio Vincent | PAO and PFO | Sell 10b5-1 | 6,894 | $2.42 | $16.7K | 146,506 −4.5% of holding | |
| Vultaggio Vincent | PAO and PFO | Sell | 3,379 | $2.39 | $8.1K | 153,400 −2.2% of holding | |
| EASTLAND JULIA MARIE | CEO & President | Sell | 889 | $2.39 | $2.1K | 79,133 −1.1% of holding | |
| Bruns Ingmar | Chief Medical Officer | Sell | 335 | $2.39 | $802 | 33,332 −1% of holding | |
| Vultaggio Vincent | PAO and PFO | Sell | 29,951 | $2.43 | $72.8K | 156,779 −16% of holding | |
| EASTLAND JULIA MARIE | CEO & President | Sell | 7,866 | $2.43 | $19.1K | 80,022 −9% of holding | |
| Bruns Ingmar | Chief Medical Officer | Sell | 2,962 | $2.43 | $7.2K | 33,667 −8.1% of holding | |
| Vultaggio Vincent | PAO and PFO | Sell 10b5-1 | 556 | $2.52 | $1.4K | 186,730 −0.3% of holding | |
| Vultaggio Vincent | PAO and PFO | Sell | 2,540 | $2.55 | $6.5K | 187,286 −1.3% of holding | |
| Buy | 6,459,973 | $1.20 | $7.8M | 13,509,973 | |||
| Sell | 7,500,000 | $1.33 | $10.0M | 6,459,973 −53.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.